Abstract
Celecoxib is a well known non-steroidal anti-inflammatory drug (NSAID) and extensively employed for the treatment of arthritis. The aim of the present study was to design, develop and optimization of micro particulates system, for colon specific delivery of celecoxib for both local (in prophylaxis of colorectal adreno-carcinoma) and systemic (in chrono-therapeutic treatment of arthritis) therapy. The aim of the present work was to elucidate the effect of formulation variables e.g., amount of eudragit polymer (X1), surfactant concentration (X2) and agitation speed (X3) on in-vitro release profiles (Y1-Y3), drug entrapment efficiency (Y4) and particle size (Y5) of micro-particulates system of celecoxib. Microspheres were formulated with the combination of ethyl cellulose (EC) and eudragit RS100/eudragit S100; by using a novel quasi emulsion solvent diffusion technique. Developed formulations were characterized and evaluated on the basis of FTIR, thermal, particle size, SEM and XRD analysis. The formulation variables were optimized by response surface methodology (RSM). Best optimized delayed release formulation was further subjected to the in vivo x-ray studies to evaluate the site specificity. It was found that in-vitro release (Y1-Y3 ) decreased significantly (p<0.05) with increase in amount of eudragit polymer but increased significantly (p<0.05) with an increase in surfactant concentration and stirring speed. FTIR study indicated that no strong chemical interaction took place between the drug and excipients of prepared formulations. DSC and XRD studies indicated that drug was present in the amorphous state. The X-ray photographs revealed that the swelling layer eroded from the outer surface and a size reduction was seen after 6 hrs when optimized microspheres reached the site of colon. Therefore, this approach suggested that the combination of eudragit S100 and ethyl cellulose microspheres may be useful for the delivery of maximum amount of celecoxib in intact form to the colon.
Keywords: Celecoxib, Central composite-face centered design, Colon targeted delivery system, In vivo x-ray studies, Response Surface Methodology (RSM).
Graphical Abstract
Current Drug Delivery
Title:Three Levels Face Centered Central Composite Design of Colon Targeted Micro-Particulates System of Celecoxib: Screening of Formulations Variables and in vivo Studies
Volume: 11 Issue: 5
Author(s): Bankim Chandra Nandy, Vinod Verma, Sanjay Dey and Bhaskar Mazumder
Affiliation:
Keywords: Celecoxib, Central composite-face centered design, Colon targeted delivery system, In vivo x-ray studies, Response Surface Methodology (RSM).
Abstract: Celecoxib is a well known non-steroidal anti-inflammatory drug (NSAID) and extensively employed for the treatment of arthritis. The aim of the present study was to design, develop and optimization of micro particulates system, for colon specific delivery of celecoxib for both local (in prophylaxis of colorectal adreno-carcinoma) and systemic (in chrono-therapeutic treatment of arthritis) therapy. The aim of the present work was to elucidate the effect of formulation variables e.g., amount of eudragit polymer (X1), surfactant concentration (X2) and agitation speed (X3) on in-vitro release profiles (Y1-Y3), drug entrapment efficiency (Y4) and particle size (Y5) of micro-particulates system of celecoxib. Microspheres were formulated with the combination of ethyl cellulose (EC) and eudragit RS100/eudragit S100; by using a novel quasi emulsion solvent diffusion technique. Developed formulations were characterized and evaluated on the basis of FTIR, thermal, particle size, SEM and XRD analysis. The formulation variables were optimized by response surface methodology (RSM). Best optimized delayed release formulation was further subjected to the in vivo x-ray studies to evaluate the site specificity. It was found that in-vitro release (Y1-Y3 ) decreased significantly (p<0.05) with increase in amount of eudragit polymer but increased significantly (p<0.05) with an increase in surfactant concentration and stirring speed. FTIR study indicated that no strong chemical interaction took place between the drug and excipients of prepared formulations. DSC and XRD studies indicated that drug was present in the amorphous state. The X-ray photographs revealed that the swelling layer eroded from the outer surface and a size reduction was seen after 6 hrs when optimized microspheres reached the site of colon. Therefore, this approach suggested that the combination of eudragit S100 and ethyl cellulose microspheres may be useful for the delivery of maximum amount of celecoxib in intact form to the colon.
Export Options
About this article
Cite this article as:
Nandy Chandra Bankim, Verma Vinod, Dey Sanjay and Mazumder Bhaskar, Three Levels Face Centered Central Composite Design of Colon Targeted Micro-Particulates System of Celecoxib: Screening of Formulations Variables and in vivo Studies, Current Drug Delivery 2014; 11 (5) . https://dx.doi.org/10.2174/1567201811666140519161628
DOI https://dx.doi.org/10.2174/1567201811666140519161628 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Flavonoids in Atherosclerosis: An Overview of Their Mechanisms of Action
Current Medicinal Chemistry Meet Our Editorial Board Member:
Current Protein & Peptide Science SARS-CoV-2 & Covid-19: Key-Roles of the ‘Renin-Angiotensin’ System / Vitamin D Impacting Drug and Vaccine Developments
Infectious Disorders - Drug Targets Is it Possible to Reduce the Incident of Colorectal Cancer by Modifying Diet and Lifestyle?
Current Cancer Therapy Reviews Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview
Current Vascular Pharmacology Galectins: Major Signaling Modulators Inside and Outside the Cell
Current Molecular Medicine Molecular Pathology of Pancreatic Cancer: From Bench-to-Bedside Translation
Current Drug Targets Structure-Activity Relationship Analyses of Glycyrrhetinic Acid Derivatives as Anticancer Agents
Mini-Reviews in Medicinal Chemistry The Role of Therapeutic Drugs on Acquired Mitochondrial Toxicity
Current Drug Metabolism Antioxidants in Health, Disease and Aging
CNS & Neurological Disorders - Drug Targets Alpha-1 Antitrypsin Deficiency: Treatment Beyond Augmentation Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review
Current Cancer Drug Targets Imaging Patterns of Cardiovascular Involvement in Mixed Connective Tissue Disease Evaluated by Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Biological Properties of Baicalein in Cardiovascular System
Current Drug Targets - Cardiovascular & Hematological Disorders The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
Current Molecular Medicine Anti-Inflammatory Effect of Certain Dihydroxy Flavones and the Mechanisms Involved
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Spirulina paltensis: Food and Function
Current Nutrition & Food Science L-Arginine Analogs – Inactive Markers or Active Agents in Atherogenesis?
Cardiovascular & Hematological Agents in Medicinal Chemistry Endotoxin Recognition Molecules MD-2 and Toll-like Receptor 4 as Potential Targets for Therapeutic Intervention of Endotoxin Shock
Current Drug Targets - Inflammation & Allergy Cellular and Molecular Mechanisms of Dementia: Decoding the Causal link of Diabetes Mellitus in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets